ECEHH appoints new director
Professor Lora Fleming is a leading expert in the environment and public health
Michael Depledge, who has been interim director, will continue in his role as chairman of the advisory board.
Fleming joins ECEHH from the University of Miami where she was a professor in both the medical and marine schools, with particular interests in environmental and occupational health and epidemiology.
She has also held senior roles in the Division of Marine Biology and Fisheries at the Rosenstiel School of Marine and Atmospheric Sciences; the Department of Epidemiology in the Department of Epidemiology and Public Health at the Miller School of Medicine; the University of Miami Oceans and Human Health Center; and the Florida Cancer Data System,.
ECEHH is an initiative of the Peninsula College of Medicine and Dentistry – a joint venture of the University of Exeter and the University of Plymouth in the UK and the NHS in the South West of England – with investment from the ERDF (European Regional Development Fund) Convergence Programme.
ECEHH develops international research to investigate the complex and interactive relationships between the environment and human health. The research takes place within Cornwall from the expanded Knowledge Spa at Treliske and in laboratory-based facilities co-located with the University of Exeter’s Environment and Sustainability Institute, which will be built at Tremough, with collaborations with other research institutions around the world.
The ECEHH focuses on three key themes: the first investigates the effects of chemicals in the environment on human health, including pharmaceuticals and nanomaterials.
The second is climate, oceans and human health. Although the ECEHH looks at climate, oceans and human health globally, it also works on threats in a broader context and of special significance to the coastal communities of Cornwall. These include climate change, the acidification of the oceans and the threat caused by the invasion of species from other regions, such as jellyfish and toxic algae.
The third is clinical photo-biology, and is a continuation and expansion of research already taking place in Cornwall. Research in this area investigates the affects of UV on the skin, and how UVA and pollutants (such as radon and arsenic) interact and influence health.
Fleming said: ‘Our work will help to anticipate and prevent problems, mitigate problems where they do occur, discover new opportunities for businesses, county government and NGOs, and investigate ways in which we can interact with the environment in a positive way.’
You may also like
Research & Development
Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research
Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development
AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic
The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Research & Development
Baseline Therapuetics launches to advance GLP-1 Phase III Programme in Alcohol Use Disorder
The clinical-stage biotech has launched to progress BT-001, a once-weekly GLP-1 receptor agonist, into FDA-aligned Phase III trials for alcohol use disorder, with studies planned to begin in 2026
Research & Development
Researchers identify early signs of Parkinson's in the blood
Researchers at Chalmers University of Technology have identified early-stage Parkinson’s disease biomarkers detectable in blood, revealing a limited diagnostic window that could enable screening and earlier intervention years before motor symptoms appear
Research & Development
iXCells and Rosebud Biosciences pair up to advance organoid-based models for rare diseases
The expansion of iXCells’ iPSCore platform with integration of 3D human organoid expertise will enable evaluation of drug toxicity and tissue-specific responses, meeting growing demand for scalable, patient-relevant human models to support translational decision-making in drug development